Q4 2026 Concord Biotech Ltd Earnings Call Transcript

Jun 1, 2026 / 09:00 AM GMT

Release Date Price: ₹1061.3 (+0.96%)

Transcript

Key Points

Positve

Concord Biotech Ltd (NSE:CONCORDBIO) successfully completed multiple regulatory inspections, including US FTA, EU GMP, Russian GMP, NASDAQ, and WHO GMP, reinforcing global compliance standards.
The company commenced operations at its injectable facility, enhancing visibility and growth prospects in the domestic market.
Concord Biotech Ltd (NSE:CONCORDBIO) has initiated supplies of APIs to two innovator companies, expanding its customer base.
The company has invested in growth platforms, including cell and gene therapy through Cellimmune Biotech, and commenced commercialization of a softgel facility.
Concord Biotech Ltd (NSE:CONCORDBIO) maintains a strong balance sheet with zero debt and cash equivalents of over Rs. 414 crores, positioning it well for future growth opportunities.

Negative

The company faced a challenging FY26 with revenue degrowth of 12% for the full year and 24% for Q4 due to multiple industry and geopolitical headwinds.
Procurement activities by customers, particularly in the U.S., slowed in the first half of FY26, impacting revenues.
Concord Biotech Ltd (NSE:CONCORDBIO) experienced supply chain disruptions in the European region due to delayed written confirmation approvals, affecting supplies for nearly three months.
The ongoing war and geopolitical conditions in the Middle East led to a major tender being on hold, adversely impacting revenues.
The company's US Veterans Affairs business was impacted as related tenders were not finalized, resulting in lower sales in the second half of the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CONB.NS - Concord Biotech Ltd
Q4 2026 Concord Biotech Ltd Earnings Call
Jun 01, 2026 / 09:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and Gentlemen, Good day and welcome to Q4 and FY26 Earnings Conference Call of Concord Biotag Limited hosted by Ambit Capital.

This conference call may contain forward-looking statements about the company which are based on beliefs, opinions and expectations of the company as on the date of this call.

These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing *0 on a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.